When do mavacamten and aficamten patent protections or exclusivity end?
Mavacamten (Camzyos) and aficamten (not yet an approved product) each have different layers of protection—patents, market exclusivity (where applicable), and regulatory exclusivity extensions. The exact end dates depend on country, the specific patent family/claims, and whether the drug received any exclusivity or protection beyond the base patent term.
From the provided information, the only concrete exclusivity timeline is that Camzyos (mavacamten) was granted market exclusivity in the U.S. through 2029. [1]
How long is U.S. market exclusivity for Camzyos (mavacamten)?
For Camzyos (mavacamten), U.S. market exclusivity runs through 2029. [1]
What about aficamten—does it have an exclusivity timeline yet?
The provided information does not include an exclusivity end date for aficamten. It therefore doesn’t allow a definitive exclusivity timeline for that drug based on the sources supplied. [2]
Why might the “exclusivity” date differ from the “patent” date?
Even when a drug has a clearly stated market exclusivity window, manufacturers can still face different constraints depending on:
- Whether a challenger can design around the specific patent claims.
- Whether patents extend beyond the market exclusivity window.
- Whether regulatory exclusivity applies in the same way across jurisdictions.
Because the supplied material only specifies one explicit market exclusivity endpoint (Camzyos through 2029) and does not provide patent-family or jurisdiction-by-jurisdiction patent expirations, the timeline beyond 2029 cannot be reconstructed from the provided information alone. [1][2]
Does the cardiology use case (hypertrophic cardiomyopathy) change the exclusivity timeline?
The provided information ties the “market exclusivity through 2029” statement specifically to Camzyos (mavacamten), which is used for hypertrophic cardiomyopathy. It does not provide additional data showing that the exclusivity duration changes due to indication or line of therapy, nor does it provide a parallel statement for aficamten. [1][2]
Practical next step: how to get the exact end date you care about
To determine the precise “patent protection and exclusivity timeline” for mavacamten and aficamten in your target country, you typically need:
- Country of interest (U.S., EU, UK, etc.).
- Whether you mean patent expiry, regulatory exclusivity, or both.
- The specific reference product/approval and the associated protected label or indication.
The provided information here only supports: Camzyos U.S. market exclusivity through 2029. [1]
---
Sources
- CMS / National Coverage with Evidence Development? Camzyos market exclusivity through 2029 (provided source)
- F. Hoffmann-La Roche / aficamten-related regulatory and pipeline information (provided source)